CEL-SCI to Launch FDA Registration-Enabling Phase 3 Confirmatory Study to Bring Multikine® to Market for Newly Diagnosed Head and Neck Cancer

Patient enrollment expected to commence at clinical centers in the U.S., Europe, Asia and later on in South America The 212-patient confirmatory study is powered at approximately 97% to confirm a previously